NovoCure Limited - Ordinary Shares (NVCR)
NVCR moved a median of -0.53% 30 minutes after news, and +0.32% by the close. How NVCR actually reacts to news — the realized, point-in-time move the market made, measured across 392 labeled events over the last three years with zero look-ahead.
NVCR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 39% | 392 |
| 30-min | -0.53% | 40% | 392 |
| 60-min | -0.07% | 49% | 392 |
| to close | +0.32% | 51% | 391 |
| Middle 50% of NVCR reactions | -2.94% to +1.38% |
|---|---|
| Median reaction (30-min) | -0.53% |
| Measured reactions | 392 |
Half of all NovoCure Limited - Ordinary Shares news events land between -2.94% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NVCR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | -3.61% | 25% | +0.12% |
| Rating reiterations | 56 | -0.44% | 38% | -0.05% |
| Price-target raises | 11 | -0.07% | 46% | -0.44% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how NVCR ranks against every other measured name →
That’s how NVCR usually reacts — get an email when it moves on news →Email me when NVCR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NVCR's baseline. Nothing else.
Recent NVCR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K NovoCure Ltd For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +2.69% | +0.70% | |
| Novocure to Report Third Quarter 2026 Financial Results | Press release | Business Wire | +2.69% | +0.70% | |
| Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer | Press release | Business Wire | +2.69% | +0.70% | |
| Form 8-K NovoCure Ltd For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | -5.62% | |
| Novocure Announces Upcoming Investor Events | Press release | Business Wire | -0.95% | -0.28% | |
| Form 8-K NovoCure Ltd For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +0.12% | |
| Form 10-Q NovoCure Ltd For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +11.11% | +11.06% | |
| Form 8-K NovoCure Ltd For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +11.11% | +11.06% | |
| Novocure Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +11.11% | +11.06% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating NovoCure Limited (NVCR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.06% | +4.05% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NovoCure Limited (NVCR) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.20% | -1.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NovoCure Limited (NVCR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.71% | +1.88% | |
| NovoCure Limited (NVCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.70% | +1.02% | |
| Novocure to Report Second Quarter 2026 Financial Results | Press release | Business Wire | +0.00% | +2.60% | |
| Form 8-K NovoCure Ltd For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | -2.07% | |
| Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer | Press release | Business Wire | -0.42% | -2.07% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages NovoCure Limited (NVCR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.52% | +0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating NovoCure Limited (NVCR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.39% | +0.92% | |
| NovoCure Limited (NVCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.40% | +0.47% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NovoCure Limited (NVCR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.28% | +1.41% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages NovoCure Limited (NVCR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.57% | +0.79% | |
| Form 8-K NovoCure Ltd For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -5.06% | -4.99% | |
| Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | Press release | Business Wire | -5.06% | -4.99% | |
| Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) | Press release | PR Newswire | +0.49% | -5.02% | |
| Form 8-K NovoCure Ltd For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | -2.38% | |
| Form DEFA14A NovoCure Ltd | SEC filing · Form DEFA14A | SEC EDGAR | -0.11% | -0.11% | |
| Form 10-Q NovoCure Ltd For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +7.81% | +14.36% | |
| Form 8-K NovoCure Ltd For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +7.81% | +14.36% | |
| Novocure Reports First Quarter 2026 Financial Results | Press release | Business Wire | +7.81% | +14.36% | |
| Form 8-K/A NovoCure Ltd For: Nov 24 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +0.56% | |
| Form DEF 14A NovoCure Ltd For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | -0.63% | -3.47% | |
| Form DEFA14A NovoCure Ltd | SEC filing · Form DEFA14A | SEC EDGAR | -0.63% | -3.47% | |
| Form 8-K NovoCure Ltd For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -3.82% | |
| Novocure to Report First Quarter 2026 Financial Results | Press release | Business Wire | +1.09% | -1.72% | |
| Form 8-K NovoCure Ltd For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +3.22% | -0.34% | |
| Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer | Press release | Business Wire | +3.22% | -0.34% | |
| Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer | Press release | Business Wire | +0.21% | -0.15% | |
| Novocure to Participate in 2026 Leerink Global Healthcare Conference | Press release | Business Wire | +0.21% | -0.15% | |
| Form 10-K NovoCure Ltd For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.38% | +3.77% | |
| Form 8-K NovoCure Ltd For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | +3.77% | |
| Form S-8 NovoCure Ltd | SEC filing · Form S-8 | SEC EDGAR | +0.38% | +3.77% | |
| Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update | Press release | Business Wire | +0.38% | +3.77% | |
| Form 8-K NovoCure Ltd For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +2.96% | +19.92% | |
| Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer) | Press release | Business Wire | +0.18% | +6.92% | |
| Form 8-K NovoCure Ltd For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -0.97% | -12.74% | |
| U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer | Press release | Business Wire | -0.97% | -12.74% | |
| Form 8-K NovoCure Ltd For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | -2.73% | -12.64% | |
| Form 8-K NovoCure Ltd For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -3.86% | -5.66% | |
| Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update | Press release | Business Wire | -3.86% | -5.66% | |
| Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +1.17% | +4.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NVCR section they belong to.
Where else NVCR is measured.
NVCR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NovoCure Limited - Ordinary Shares's median reaction calculated?
Every labeled NVCR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 392 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of NVCR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NVCR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.